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Methods: Dogs were instrumented with a carotid flow probe, stimulating electrode, and a stenosis. Current (150 pA) was applied to the intimal surface of the right carotid artery, and time to occlusive thrombus formation was noted. BAY U 3405 was administered, and the procedure for thrombus formation was repeated for the left carotid artery.
Results: BAY U 3405 administration prevented occlusive arterial thrombosis formation. Ex vivo platelet aggregation was inhibited, bleeding time increased, and thrombus weight reduced after BAY U 3405 treatment. In a second group, thrombi were formed initially in both carotid arteries, BAY U 3405 was administered as before, and anisoylated plasminogen streptokinase activator complex was infused in the right carotid artery proximal to the occlusive thrombus. BAY U 3405 did not alter the incidence of rethrombosis compared with the lytic agent alone.
Conclusions: BAY U 3405 prevented primary arterial thrombosis, corresponding to inhibition of platelet aggregation, and increased bleeding times. BAY U 3405, however, did not prevent rethrombosis after successful thrombolysis with anisoylated plasminogen streptokinase activator complex, despite the fact that platelet reactivity was inhibited. The data are consistent with the concept that the residual thrombus represents a more effective thrombogenic stimulus as compared with arterial wall injury alone and that the mechanisms associated with primary versus secondary thrombus formation may require separate therapeutic approaches. (Stroke 1993; 24:820-828) KEY WORDs * platelet aggregation * thrombosis * thromboxane antagonists * dogs Trhromboxane A2 (TXA2), an autacoid with proaggregatory and vasoconstricting properties, is formed from the isomerization of prostaglandin endoperoxide (PGH2). Biosynthesis of the autacoid is dependent on the action of the P450 monoxygenase thromboxane synthetase, present in the blood platelet.' Synthesis of TXA2 at local vascular sites may play an important role in modulating vascular resistance and enhancing platelet reactivity. 23 The primary trigger of spontaneous reductions in arterial blood flow associated with transient ischemic attacks may be related to fissuring at the site of an atherosclerotic plaque leading to a dynamic process involving platelet accumulation and thrombus formation as has been suggested for the diseased coronary artery.4,5 Despite the participation of endothelium-derived vasoactive autacoids (prostacyclin, nitric oxide, endothelin), platelet activation and aggregation at the site of the fissured plaque plays the dominant role in the sequence of events in intra-arterial thrombotic occlusion. 3 San Diego, Calif) was placed on each common carotid artery proximal to both the point of insertion of the intravascular electrode and the mechanical constrictor. The mechanical constrictor was constructed of stainless steel in a C shape with a polytetrafluoroethylene screw (Teflon; 2 mm in diameter) that could be adjusted to alter vessel circumference and produce a regional stenosis. The constrictor was adjusted until the pulsatile flow pattern was reduced by 50% without altering the mean blood flow velocity. Blood flow velocity in the carotid vessels was monitored continuously.
Electrolytic injury to the intimal surface of each vessel was accomplished with the use of an intravascular electrode consisting of a polytetrafluoroethylene (Teflon)-insulated silver-coated copper wire connected to the anode of a 9-V nickel-cadmium battery in series with a 250,000-fl variable resistor. Penetration of the vessel wall by the electrode was facilitated by attaching the end of a 25-gauge hypodermic needle to the uninsulated part of the electrode. The intravascular portion of the anodal electrode was positioned to have the uninsulated region in intimate contact with the endothelial surface of the vessel. The cathode was placed at a distant subcutaneous site.
A total of six dogs were used as control animals to determine the validity of the hypothesis that right carotid arteries are similar to left carotid arteries with respect to thrombus development, even after complete occlusion and removal of the right carotid artery. Dogs were instrumented in the usual manner, and anodal current was applied to the vessels in a sequential manner. The right carotid artery underwent anodal vessel wall injury until complete occlusion was achieved for a period of 30 minutes, at which point it was removed and the thrombus weighed. The length, and the intact thrombus mass was lifted off the intimal surface of the vessel. The weight of the thrombus mass was determined with an analytical balance. The left carotid artery of each animal served as the test vessel. The vessel was instrumented in a manner identical to that described for the contralateral vessel. BAY U 3405 (3.0 mg/kg IV and 30.0 mg/kg IV) was administered as a single dose slowly over the course of 2 to 3 minutes. The application of the anodal current to the left carotid artery was initiated 15 minutes after the administration of BAY U 3405.
A second protocol was used to evaluate the effects of thromboxane antagonism for the prevention of rethrombosis after lysis of a preexisting thrombus. The injury current was applied to both carotid arteries simultaneously for a maximum period of 3 hours or was terminated 30 minutes after blood flow in each vessel had remained stable at zero flow velocity to substantiate formation of a stable occlusive thrombus (Figure 1 ). BAY U 3405 (3.0 or 30.0 mg/kg IV) was administered as a single dose slowly over the course of 2 to 3 minutes. Ten minutes after BAY U 3405 was administered, APSAC (0.05 U/kg) was infused intra-arterially, directly proximal to the thrombus (right carotid artery only) to achieve lysis in that vessel only without disturbing the thrombus in the contralateral vessel. The local intra-arterial dose of APSAC was administered over 90 seconds. The dose of APSAC was selected to avoid alteration in the plasma clotting factors as detertin time (aPTT), thrombin time (TT), and prothrombin time (PT).
An additional group of heartworm-negative dogs was screened for baseline platelet aggregation to assess platelet responsiveness to arachidonic acid. The initial screening procedure identified six animals whose platelets showed a positive response to arachidonic acid at concentrations of 0.65 and 0.325 mmol/L. Each of the dogs satisfying the inclusion criteria received 30 mg/kg IV BAY U 3405. Platelet aggregations were determined daily for the next 7 days at the same hour each day to avoid any influence of diurnal variations on platelet reactivity.
Blood (20 ml) was withdrawn for platelet studies from the jugular cannula into a plastic syringe containing 3.2% sodium citrate as the anticoagulant (1: To assess the anticoagulation state of the animals, PT, aPTT, and TT were determined using a Hemochron (Technidyne, Edison, NJ) and the reagents supplied by the manufacturer. Citrated whole blood was used for these determinations. Values are represented as a percentage of baseline readings.
Bleeding times were measured in anesthetized dogs with a Simplate device by making incisions on the tongue and blotting the wound with filter paper at 30-second intervals until blood no longer was transferred to the filter paper.
Animals to be included in the final protocol had to satisfy all of the following preestablished criteria: 1) a circulating platelet count of not less than 100 000 per cubic millimeter, 2) demonstrated ability for platelets to aggregate in response to arachidonic acid before administration of BAY U 3405, 3) thrombotic occlusion of the right carotid artery (control vessel) within 3 hours from the onset of vessel wall injury with a 150-,uA direct anodal current, and 4) absence of heartworms at final postmortem examination. [16] [17] [18] Data are expressed as mean+-SEM. The design of the protocol permitted each animal to serve as its own control. The right carotid artery was compared with the contralateral vessel with respect to time to occlusion, blood flow velocity, and resulting thrombus mass. Ex vivo platelet aggregation in response to arachidonic acid mined by measurements of activated partial thromboplaswas assessed before and after administration of BAY U associated with a dose-dependent reduction in thrombus weight (Figure 4) . The results from the initial protocol indicate that BAY U 3405 in doses of 3.0 and 30.0 mg/kg prevents primary thrombus formation in response to vessel wall injury. The in vivo efficacy of BAY U 3405 correlates with its ability to inhibit ex vivo platelet aggregation in response to arachidonic acid.
The second protocol was conducted to ascertain the ability of BAY U 3405 to prevent thrombus formation in response to a more intense and protracted thrombogenic stimulus, ie, after lysis of a preexisting thrombus. 19 Baseline carotid artery blood flow velocity did not differ between control and drug-treated groups. Administration of BAY U 3405 before induction of thrombolysis with locally administered APSAC did not influence the time to lysis and the reestablishment of carotid artery done once daily for 7 consecutive days after administration of a single intravenous dose of BAY U 3405. The results are summarized in Figure 7A . BAY U 3405 produced a persistent and significant inhibition of arachidonic acid-induced platelet aggregation that extended to 6 days after a single administration of the compound. By the seventh day ex vivo platelet aggregation determinations began to return to baseline values. Platelet counts during this time period remained unchanged from the predrug values ( Figure 7B ). Discussion The purpose of this study was twofold. The first intent was to examine the effectiveness of endoperoxide/TXA2 The precise mechanism accounting for the prolonged effect on ex vivo platelet reactivity is as yet unknown. Our present working hypothesis is that BAY U 3405 acts on endoperoxide/TXA2 receptor of the circulating platelet as well as the receptor on the megakaryocyte. It is the latter site of action that may be influencing the subsequent activity of newly released platelets into the general circulation.
In summary, we have demonstrated that BAY U 3405, a noncompetitive inhibitor of TXA2, is capable of preventing occlusive thrombus formation in response to electrolytic injury of the canine carotid artery. The protective effect is accompanied by inhibition of ex vivo platelet aggregation using arachidonic acid as the agonist. Despite the prolonged action of BAY U 3405 on ex vivo platelet function, the drug does not prevent rethrombosis when a previously occlusive arterial thrombus has undergone successful thrombolysis with locally applied APSAC. The observations demonstrate that the lysed thrombus serves as a more intense thrombogenic surface to the circulating blood than the original vessel wall injury. The preclinical assessment of antiplatelet agents as adjunctive agents for prevention of rethrombosis must be examined by appropriate models that differ from those used to assess pharmacological interventions for the prevention of primary thrombosis in response to vessel injury. Treatment with BAY U 3405 did not prevent rethrombosis despite the inhibition of ex vivo platelet activation in response to arachidonic acid. Multiple agonists participate in vivo in initiating platelet activation and thrombus formation. The ability of BAY U 3405 to prevent primary arterial thrombosis in response to vessel wall injury but not secondary thrombosis after thrombolysis suggests that different mechanisms are responsible for the proaggregatory events.
The development of pharmacological interventions for the prevention of primary and secondary thrombosis may require discrete approaches for prevention.
